Cover Image
市場調查報告書

A型肝炎:開發中產品分析

Hepatitis A - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 219723
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
A型肝炎:開發中產品分析 Hepatitis A - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 27 Pages
簡介

A型肝炎是感染A型肝炎病毒造成的肝臟發炎(刺激、朣起)。主要症狀有倦怠感及噁心、嘔吐、肝臟發炎、食欲不振、尿液暗沈、肌肉酸痛、黃膽等。主要造成疾病的原因包括了免疫系統弱化、使用違法藥物(無論是注射藥品或非注射藥品)。主要的治療法有鎮吐劑及鎮痛劑等。

本報告提供全球各國治療A型肝炎所用之開發中產品開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

A型肝炎 - 概要

A型肝炎 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

A型肝炎 - 治療藥的評估

  • 標的別
  • 各分子類型

A型肝炎的開發治療藥的企業

  • Beijing Minhai Biotechnology Co Ltd
  • Indian Immunologicals Ltd
  • Sinovac Biotech Ltd
  • Zydus Cadila Healthcare Ltd

藥物簡介

A型肝炎 - 暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9814IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Pipeline Review, H2 2017, provides an overview of the Hepatitis A (Infectious Disease) pipeline landscape.

Hepatitis A is inflammation of the liver caused by hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes (jaundice). Risk factors include weakened immune system and use injected or non-injected illicit drugs. Treatment includes antiemetics and pain relievers.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis A - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatitis A (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis A (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 1, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Hepatitis A (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis A (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis A (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis A (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis A (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis A (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis A (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis A (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis A - Overview
    • Hepatitis A - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hepatitis A - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hepatitis A - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Cadila Healthcare Ltd
    • China National Pharmaceutical Group Corp
    • Indian Immunologicals Ltd
    • Sinovac Biotech Ltd
  • Hepatitis A - Drug Profiles
    • (hepatitis A + hepatitis B + hepatitis E) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (hepatitis A + hepatitis B) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A + hepatitis B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatitis A - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hepatitis A, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017
  • Hepatitis A - Pipeline by Cadila Healthcare Ltd, H2 2017
  • Hepatitis A - Pipeline by China National Pharmaceutical Group Corp, H2 2017
  • Hepatitis A - Pipeline by Indian Immunologicals Ltd, H2 2017
  • Hepatitis A - Pipeline by Sinovac Biotech Ltd, H2 2017
  • Hepatitis A - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Hepatitis A, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top